Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab (MATCH Study)
This Study is
No Longer Enrolling
Details
Age
Child to Adult
Phase
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 16-2448
More information available at ClinicalTrials.gov: NCT03392142
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers